Bradykinin analysis revived - A validated method for determination of its stable metabolite in whole blood by LC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 947-948, Issue , 2014, Pages 139-144

  Seip, Knut F ^a   Bjerknes, Kari C ^a   Johansen, Harald T ^a   Nielsen, Erik W ^b   Landrø, Linn ^c   Reubsaet, Léon ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b NORDLAND HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

BK1 5; Bradykinin; Hereditary angioedema; LC MS MS; Validation

Indexed keywords

BK1-5; BRADYKININ; HEREDITARY ANGIOEDEMA; LC-MS/MS; VALIDATION;

METABOLITES;

BLOOD;

BRADYKININ;

ACCURACY; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HUMAN; ION TRAP MASS SPECTROMETRY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; METABOLITE; PHASE SEPARATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REMISSION; SOLID PHASE EXTRACTION; STANDARD; TANDEM MASS SPECTROMETRY;

BK1-5; BRADYKININ; HEREDITARY ANGIOEDEMA; LC-MS/MS; VALIDATION;

BRADYKININ; CHROMATOGRAPHY, LIQUID; HUMANS; TANDEM MASS SPECTROMETRY; VASODILATOR AGENTS;

EID: 84892378296     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.12.033     Document Type: Article

References (25)

1. Leeb-Lundberg L.M., Marceau F., Muller-Esterl W., Pettibone D.J., Zuraw B.L. Pharmacol. Rev. 2005, 57:27.
2. Schmaier A.H. Int. Immunopharmacol. 2008, 8:161.
3. Brown N.J., Gainer J.V., Murphey L.J., Vaughan D.E. Circulation 2000, 102:2190.
4. Joseph K., Kaplan A.P. Adv. Immunol. 2005, 86:159.
5. Sainz I.M., Pixley R.A., Colman R.W. Thromb. Haemost. 2007, 98:77.
6. Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J. N. Engl. J. Med. 1998, 339:1285.
7. Kiowski W., Linder L., Kleinbloesem C., van Brummelen P., Buhler F.R. Circulation 1992, 85:1.
8. Kaplan A.P., Joseph K., Silverberg M. J. Allergy Clin. Immunol. 2002, 109:195.
9. Riad A., Zhuo J.L., Schultheiss H.P., Tschope C. Curr. Opin. Nephrol. Hypertens. 2007, 16:22.
10. Barratt-Due A., Johansen H.T., Sokolov A., Thorgersen E.B., Hellerud B.C., Reubsaet J.L., Seip K.F., Tonnessen T.I., Lindstad J.K., Pharo A., Castellheim A., Mollnes T.E., Nielsen E.W. Shock 2011, 36:517.
11. Asmis L.M., Asmis R., Sulzer I., Furlan M., Lammle B. Swiss Med. Wkly. 2008, 138:142.
12. Bas M., Adams V., Suvorava T., Niehues T., Hoffmann T.K., Kojda G. Allergy 2007, 62:842.
13. Longhurst H., Cicardi M. Lancet 2012, 379:474.
14. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Lancet 1998, 351:1693.
15. Borzutzky A., Schneider L.C., Geha R.S. Clin. Chem. 2008, 54:1733.
16. Hoover T., Lippmann M., Grouzmann E., Marceau F., Herscu P. Clin. Exp. Allergy 2010, 40:50.
17. Cyr M., Lepage Y., Blais C., Gervais N., Cugno M., Rouleau J.L., Adam A. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H275.
18. Murphey L.J., Hachey D.L., Oates J.A., Morrow J.D., Brown N.J. J. Pharmacol. Exp. Ther. 2000, 294:263.
19. Murphey L.J., Hachey D.L., Vaughan D.E., Brown N.J., Morrow J.D. Anal. Biochem. 2001, 292:87.
20. Guideline on bioanalytical method validation, Committee for Medicinal Products for Human Use (CHMP) 2011, European Medicines Agency, London.
21. Guidance for Industry Bioanalytical Method Validation 2001, U.S. Department of Health and Human Services, Food and Drug Administration, Rockville.
22. Sheikh I.A., Kaplan A.P. Biochem. Pharmacol. 1989, 38:993.
23. Xia Y.Q., Jemal M. Rapid Commun. Mass Spectrom. 2009, 23:2125.
24. Nussberger J., Cugno M., Cicardi M. N. Engl. J. Med. 2002, 347:621.
25. Nussberger J., Cugno M., Cicardi M., Agostoni A. J. Allergy Clin. Immunol. 1999, 104:1321.